Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand...
| Autores: | , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Recursos: | Universitat Pompeu Fabra |
| Repositorio: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/61279 |
| Acesso em linha: | http://hdl.handle.net/10230/61279 http://dx.doi.org/10.1016/j.biopha.2023.115775 |
| Access Level: | acceso abierto |
| Palavra-chave: | Ayahuasca Dimethyltryptamine Lysergic acid diethylamide Metabolism Metabolomics Psilocybin Psychedelics |
| id |
ES_47c3d6aba96448aa2e2c1bdd4117dbf9 |
|---|---|
| oai_identifier_str |
oai:repositori.upf.edu:10230/61279 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humansMadrid-Gambin, FranciscoFabregat-Safont, DavidGómez-Gómez, ÀlexOlesti Muñoz, Eulàlia, 1991-Mason, Natasha L.Ramaekers, Johannes G.Pozo Mendoza, Óscar J., 1975-AyahuascaDimethyltryptamineLysergic acid diethylamideMetabolismMetabolomicsPsilocybinPsychedelicsPsychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is needed when considering the development of future novel therapeutic approaches. Both metabolic and metabolomics studies may help for these purposes. On one hand, metabolic studies aim to determine the main metabolites of the drug. On the other hand, the application of metabolomics in human psychedelics studies can help to further understand the biological processes underlying the psychedelic state and the mechanisms of action underlying their therapeutic potential. This review presents the state of the art of metabolic and metabolomic studies after lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT) and β-carboline alkaloids (ayahuasca brew), 5-methoxy-DMT and psilocybin administrations in humans. We first describe the characteristics of the published research. Afterward, we reviewed the main results obtained by both metabolic and metabolomics (if available) studies in classical psychedelics and we found out that metabolic and metabolomics studies in psychedelics progress at two different speeds. Thus, whereas the main metabolites for classical psychedelics have been robustly established, the main metabolic alterations induced by psychedelics need to be explored. The integration of metabolomics and pharmacokinetics for investigating the molecular interaction between psychedelics and multiple targets may open new avenues in understanding the therapeutic role of psychedelics.Elsevier202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/61279http://dx.doi.org/10.1016/j.biopha.2023.115775reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésBiomed Pharmacother. 2023 Dec 31;169:115775© 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/612792026-06-12T07:21:37Z |
| dc.title.none.fl_str_mv |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| title |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| spellingShingle |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans Madrid-Gambin, Francisco Ayahuasca Dimethyltryptamine Lysergic acid diethylamide Metabolism Metabolomics Psilocybin Psychedelics |
| title_short |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| title_full |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| title_fullStr |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| title_full_unstemmed |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| title_sort |
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans |
| dc.creator.none.fl_str_mv |
Madrid-Gambin, Francisco Fabregat-Safont, David Gómez-Gómez, Àlex Olesti Muñoz, Eulàlia, 1991- Mason, Natasha L. Ramaekers, Johannes G. Pozo Mendoza, Óscar J., 1975- |
| author |
Madrid-Gambin, Francisco |
| author_facet |
Madrid-Gambin, Francisco Fabregat-Safont, David Gómez-Gómez, Àlex Olesti Muñoz, Eulàlia, 1991- Mason, Natasha L. Ramaekers, Johannes G. Pozo Mendoza, Óscar J., 1975- |
| author_role |
author |
| author2 |
Fabregat-Safont, David Gómez-Gómez, Àlex Olesti Muñoz, Eulàlia, 1991- Mason, Natasha L. Ramaekers, Johannes G. Pozo Mendoza, Óscar J., 1975- |
| author2_role |
author author author author author author |
| dc.subject.none.fl_str_mv |
Ayahuasca Dimethyltryptamine Lysergic acid diethylamide Metabolism Metabolomics Psilocybin Psychedelics |
| topic |
Ayahuasca Dimethyltryptamine Lysergic acid diethylamide Metabolism Metabolomics Psilocybin Psychedelics |
| description |
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is needed when considering the development of future novel therapeutic approaches. Both metabolic and metabolomics studies may help for these purposes. On one hand, metabolic studies aim to determine the main metabolites of the drug. On the other hand, the application of metabolomics in human psychedelics studies can help to further understand the biological processes underlying the psychedelic state and the mechanisms of action underlying their therapeutic potential. This review presents the state of the art of metabolic and metabolomic studies after lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT) and β-carboline alkaloids (ayahuasca brew), 5-methoxy-DMT and psilocybin administrations in humans. We first describe the characteristics of the published research. Afterward, we reviewed the main results obtained by both metabolic and metabolomics (if available) studies in classical psychedelics and we found out that metabolic and metabolomics studies in psychedelics progress at two different speeds. Thus, whereas the main metabolites for classical psychedelics have been robustly established, the main metabolic alterations induced by psychedelics need to be explored. The integration of metabolomics and pharmacokinetics for investigating the molecular interaction between psychedelics and multiple targets may open new avenues in understanding the therapeutic role of psychedelics. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2024 2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10230/61279 http://dx.doi.org/10.1016/j.biopha.2023.115775 |
| url |
http://hdl.handle.net/10230/61279 http://dx.doi.org/10.1016/j.biopha.2023.115775 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Biomed Pharmacother. 2023 Dec 31;169:115775 |
| dc.rights.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositorio Digital de la UPF instname:Universitat Pompeu Fabra |
| instname_str |
Universitat Pompeu Fabra |
| reponame_str |
Repositorio Digital de la UPF |
| collection |
Repositorio Digital de la UPF |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869407316187545600 |
| score |
15,812429 |